title: INNO-206, the (6-maleimidocaproyl hydrazone derivative of doxorubicin), shows superior antitumor efficacy compared to doxorubicin in different tumor xenograft models and in an orthotopic pancreas carcinoma model.
abstract: The (6-maleimidocaproyl)hydrazone derivative of doxorubicin (INNO-206) is an albumin-binding prodrug of doxorubicin with acid-sensitive properties that is being assessed clinically. The prodrug binds rapidly to circulating serum albumin and releases doxorubicin selectively at the tumor site. This novel mechanism may provide enhanced antitumor activity of doxorubicin while improving the overall toxicity profile. Preclinically, INNO-206 has shown superior activity over doxorubicin in a murine renal cell carcinoma model and in breast carcinoma xenograft models. In this work, we compared the antitumor activity of INNO-206 and doxorubicin at their respective maximum tolerated doses in three additional xenograft models (breast carcinoma 3366, ovarian carcinoma A2780, and small cell lung cancer H209) as well as in an orthotopic pancreas carcinoma model (AsPC-1). INNO-206 showed more potent antitumor efficacy than free doxorubicin in all tumor models and is thus a promising clinical candidate for treating a broad range of solid tumors.
authors.affiliation: Department of Medical Oncology, Clinical Research, Tumor Biology Center, Breisacher Strasse 117, 79106, Freiburg, Germany.
authors.forename: R
authors.initials: R
authors.lastname: Graeser
authors.forename: N
authors.initials: N
authors.lastname: Esser
authors.forename: H
authors.initials: H
authors.lastname: Unger
authors.forename: I
authors.initials: I
authors.lastname: Fichtner
authors.forename: A
authors.initials: A
authors.lastname: Zhu
authors.forename: C
authors.initials: C
authors.lastname: Unger
authors.forename: F
authors.initials: F
authors.lastname: Kratz
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000737:chemistry / Q000627:therapeutic use*; D045744:Cell Line, Tumor; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D004195:Disease Models, Animal; D004317:Doxorubicin / Q000031:analogs & derivatives* / Q000737:chemistry / Q000627:therapeutic use; D005260:Female; D006801:Humans; D006835:Hydrazones / Q000737:chemistry / Q000627:therapeutic use*; D020128:Inhibitory Concentration 50; D051379:Mice; D010190:Pancreatic Neoplasms / Q000188:drug therapy*; D016896:Treatment Outcome; D023041:Xenograft Model Antitumor Assays; D000093542:Gemcitabine
chemical_list: D000970:Antineoplastic Agents; D006835:Hydrazones; D003841:Deoxycytidine; C085780:doxorubicin(6-maleimidocaproyl)hydrazone; D004317:Doxorubicin; D000093542:Gemcitabine